Big data analysis of outcomes in non-small cell lung cancer at a regional cancer institute with a coordinated precision medicine program. Interplatform and cross-cohort meta-analysis of tumor ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

TUESDAY, Oct. 14, 2025 (HealthDay News) -- The incidence rates for invasive lobular carcinoma (ILC) increased from 2012 to 2021 for all racial and ethnic groups, according to a study published online ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

– ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment – – Data will be featured in ...

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

Artificial intelligence is making its mark on the future of cancer care. One of the newest applications for the technology is pinpointing hard-to-detect breast cancer. Researchers at Ohio State ...